AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of KIT2014 in Patients With Moderate to Severe COPD

RecruitingPhase 1, Phase 2Ages 40 Years - 80 YearsAllKither Biotech Srl
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Study investigating the safety, tolerability, pharmacokinetics and early efficacy with KIT2014 over 7 days of treatment in moderate to severe chronic obstructive pulmonary disease patients.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Must have given written informed consent before any study-related activities are performed and must be able to understand the full nature and purpose of the study, including possible risks and adverse effects * Adult males and females, 40 to 80 years of age (inclusive) at screening. * Current or former cigarette smokers with a โ‰ฅ10 pack-year smoking history * Established physician diagnosis of COPD with associated symptoms defined by the GOLD guidelines for โ‰ฅ 12 months of screening. * FEV1 post-bronchodilator of 40% to 80% of predicted normal at Screening * Current symptoms of COPD, including bronchitis and/or dyspnoea on moderate exertion at screening. Exclusion Criteria: * History of life-threatening COPD * Chronic obstructive pulmonary disease exacerbation requiring oral or parenteral corticosteroids or hospitalisation within 3 months of Screening * Other clinically active, physician diagnosed moderate to severe respiratory disorders that could interfere with study assessments or confound results (e.g., asthma, bronchiectasis, pulmonary fibrosis, interstitial lung diseases, bronchiolitis obliterans, lung cancer, cor pulmonale, pulmonary hypertension, uncontrolled sleep apnoea, active tuberculosis). Other inclusion/exclusion eligibility criteria apply.
๐Ÿ’Š

What it tests

  • KIT2014
  • Placebo
๐Ÿ“

Where

3 sites
Novatrials
Charlestown, Australia
Emeritus Research Sydney
Sydney, Australia
Emeritus Research
Camberwell, Australia
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy